Guidance regarding safe handling of hazardous drugs has been a century in the making. Research in the modern chemotherapy era began in the 1930s with nitrogen mustard treatments for lymphoma. 1 A letter published in a 1970 Pediatrics issue by a Hematology resident asked for hazards and handling precautions to be published over concern from toxicity due to skin contact with chemotherapy. 2 In 1990, approximately 60 years after research started with chemotherapy, the American Society of Health-System Pharmacists (ASHP) published the first criteria for classification of hazardous drugs. The original National Institute for Occupational Safety and Health (NIOSH) list of hazardous drugs was published in 2004 and now includes drugs other than chemotherapy, highlighting that hazardous drugs require a broader scope than previously recognized. 3 By the close of 2019, the new United States Pharmacopeia (USP) Chapter 800: Hazardous Drugs-Handling in Health Care Settings (USP <800>) will become the official standard almost 90 years after cytotoxic medications were first used. 4 The original criterion for hazardous drugs defined by ASHP was an outcome of an Occupational Safety and Health Administration (OSHA) inspection of a California pharmacy 5 :
1. Carcinogenicity in animal models, in the patient population, or both as reported by the International Agency for Research on Cancer 2. Teratogenicity in animal studies or treated patients 3. Fertility impairment in animal studies or treated patients 4. Evidence of serious organ or other toxicity at low doses in animal models or treated patients 5. Genotoxicity defined as mutagenicity and clastogenicity in short-term test systems NIOSH broadened the defining criteria and added an additional category to account for drugs released onto the market after the NIOSH list creation:
1. Carcinogenicity 2. Teratogenicity or developmental toxicity 3. Reproductive toxicity 4. Organ toxicity at low doses 5. Genotoxicity 6. Structure and toxicity profiles of new drugs that mimic existing hazardous drugs
The NIOSH list has historically been updated biannually, although it is currently about 4 years behind at the date of this publication with the 2016 list including all drugs on the market up to the end of 2013. USP <800> requires each entity to maintain a list of hazardous drugs that is reviewed annually to include all NIOSH medications the entity uses. 4 Furthermore, if a new drug enters the market or is used on an investigational basis, NIOSH criteria must be applied to determine whether a drug is hazardous. If no information on the drug exists, by default it is to be considered hazardous. This presents a significant challenge for entities implementing USP <800> as there will be almost 7 years of new drugs on the market by the time of implementation on December 1, 2019, and education to personnel is required with each new drug added to the hazardous drug list.
The simple goal of exposure reduction is complicated by the reality that exposure to hazardous drugs can occur at any step in the process from procurement to administration. USP <800> applies to all health care personnel who handle hazardous drugs and all entities that store, prepare, transport, or administer hazardous drugs. 4 Operationalization of the standard requires either treating all hazardous drugs on the NIOSH list according to USP <800> standards or conducting a risk assessment of every drug, the results of which would allow the entity to deviate from treating select drugs as hazardous under USP <800>. While all hazardous drug active pharmaceutical ingredients (APIs) and antineoplastics requiring manipulation cannot be exempt from this requirement, any drug in a final dosage form or not in Table 1 of the NIOSH list can have handling procedures that differ from USP <800> standards. The first step in risk assessment is to identify why the drug has been classified as hazardous to avoid making decisions based on convenience for handling hazardous drugs per current practice, negating the spirit of the standard and leaving personnel and patients at increased risk of complications from hazardous drug exposure. As USP <800> will drastically change how drugs are handled, timely education and buy-in from health care personnel, especially pharmacists, will help drive the time-sensitive implementation of standards.
An 18-month delay to the original implementation date not only gives entities who handle hazardous drugs extra time to 763850H PXXXX10.1177/0018578718763850Hospital PharmacyAndrews and Dill editorial2018 1 The University of Kansas Health System, Kansas City, USA 2 The University of Kansas, Kansas City, USA prepare for the new standards but also highlights the ongoing challenge of implementing change in health care. USP <800> provides minimal guidance regarding how to complete an assessment of risk or establish an employee monitoring program. However, this may also be viewed as a potential strength as each entity that must adhere to USP <800> has the leeway to interpret and implement USP <800> in light of their unique personnel responsibilities and physical construction. Books, smartphone apps, continuing education, online courses, and conferences exist to provide guidance in the implementation of the USP <800> standard, but critical thinking is required to determine what makes a drug hazardous.
USP <800> provides long-awaited standards for the health care community in the safe handling of hazardous drugs. Effective implementation is imperative to protect health care personnel as well as patients and caregivers alike. Pharmacists are the clear choice to take on the challenge of evaluating hazardous risk of drugs and implementing appropriate procedures to manage those risks. However, the task of every entity independently evaluating every dosage for each of the hundreds of drugs on the NIOSH list will be a significant burden on pharmacy resources. We as a profession are called to the development of best practices, and we look forward to the opportunity to share our approach in meeting this challenge.
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